Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study

BACKGROUND: Vascular endothelial growth factor (VEGF) plays a role in the tumor microenvironment. Sorafenib, which inhibits the VEGF pathway, has an immune-modulation function but lacks substantial clinical data. This study aims to explore the efficacy of anti-PD-1 combined sorafenib in advanced hep...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, San-Chi, Huang, Yi-Hsiang, Chen, Ming-Huang, Hung, Yi-Ping, Lee, Rheun-Chuan, Shao, Yu-Yun, Chao, Yee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753926/
https://www.ncbi.nlm.nih.gov/pubmed/35016637
http://dx.doi.org/10.1186/s12885-022-09173-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753926/
https://www.ncbi.nlm.nih.gov/pubmed/35016637
http://dx.doi.org/10.1186/s12885-022-09173-4

Ejemplares similares